Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03611868
Title A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Ascentage Pharma Group Inc.
Indications

transitional cell carcinoma

Advanced Solid Tumor

well-differentiated liposarcoma

melanoma

lung adenocarcinoma

lung non-small cell carcinoma

malignant peripheral nerve sheath tumor

dedifferentiated liposarcoma

Therapies

APG-115 + Pembrolizumab

Age Groups: senior | child | adult
Covered Countries USA

Additional content available in CKB BOOST